As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.

Claiming Pfizer’s Abrysvo infringes four of its patents, GSK asks court to permanently enjoin Pfizer from making or selling the vaccine in the US but would exempt the pending maternal indication.

China- and US-based biotech LianBio is advancing three late-stage clinical assets in hopes that successful commercialization could lead to profitability and validate its in-licensing business model in a challenging environment.

Big biologic makers line up on opposite sides of dispute between Amgen and Sanofi over whether Amgen’s Repatha patents cover analogous antibodies with the same functional characteristics.